Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects

European Journal of Clinical Nutrition

Volumn 67, Issue 4, 2013, Pages 390-394

  Wang, S Y ^a,b   Duan, K M ^b   Li, Y ^b   Mei, Y ^b   Sheng, H ^b   Liu, H ^c   Mei, X ^b   Ouyang, W ^b   Zhou, H H ^a   Liu, Z Q ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^c Changsha Municipal Center for Disease Prevention and Control   (China)

Author keywords

drug transporter; gene polymorphisms; MDR1; pharmacokinetcs; quercetin; talinolol

Indexed keywords

GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; QUERCETIN; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CHINA; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROPANOLAMINES; QUERCETIN; YOUNG ADULT;

EID: 84876407063     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2013.5     Document Type: Article

References (38)

1. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457-473.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
3. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59-98.
4. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6: 71-84.
5. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011; 201: 261-283.
6. de Lannoy IA, Silverman M. The MDR1 gene product P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551-557.
7. Fromm MFP. Glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38: 69-74.
8. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4-33.
9. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide(MDR1, ABCB1) variant 3435C4T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.
10. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584-594.
11. Sakaeda T. MDR1 Genotype-related pharmacokinetics: fact or fiction Drug Metab Pharmacokinet 2005; 20: 391-414.
12. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996; 2: 659-668.
13. Ader P, Wessmann A, Wolffram S. Bioavalability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med 2000; 28: 1056-1067.
14. Lamson DW, Brignall MS. Antioxidants cancer III: quercetin. Altern Med Rev 2000; 3: 196-208.
15. Duan KM, Wang SY, Ouyang W, Mao YM, Yang LJ. Effect of quercetin on CYP3A activity in chinese healthy participants. J Clin Pharmacol 2012; 52: 940-946.
16. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS. Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 1998; 30: 87-92.
17. Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010; 15: 857-870.
18. Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011; 34: 607-613.
19. Wang YH, Chao PD, Hsiu SL, Wen KC, Hou YC. Lethal quercetin-digoxin interaction in pigs. Life Sci 2004; 74: 1191-1197.
20. Dupuy J, Larrieu G, Sutra JF, Lespine A, Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet Parasitol 2003; 112: 337-347.
21. Yu CP, Wu PP, Hou YC, Lin SP, Tsai SY, Chen CT et al. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric Food Chem 2011; 59: 4644-4648.
22. Sambrook J, Fritsch EF, Maniatus T. Molecular cloning: a laboratory manual, second (ed.). Cold Spring Harbour Labortory Press: New York, 1989.
23. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 2000; 97: 3473-3478.
24. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55: 53-81.
25. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011; 50: 161-178.
26. Bebawy M, Sze DM. Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics. Curr Cancer Drug Targets 2008; 8: 47-52.
27. Chen C, Zhou J, Ji C. Quercetin: a potential drug to reverse multidrug resistance. Life Sci 2010; 87: 333-338.
28. Wang EJ, Casciano CN, Clement RP, Johnson WW. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 2001; 18: 432-438.
29. Abs M, Nait chabane MK, Aminatou AK, Peluso J, Leveque D, Dumont S et al. In vitro flavonoids effect on P-gp/MDR1 activity in hepatic inflammatory cellular model (unpublished).
30. Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 609-614.
31. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000; 395: 193-201.
32. Annaert PP, Brouwer KL. Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2005; 33: 388-394.
33. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009; 26: 872-882.
34. Zhou SF. Role of multidrug resistance associated proteins in drug development. Drug Discov Ther 2008; 2: 305-332.
35. Justino GC, Santos MR, Canario S, Borges C, Florêncio MH, Mira L. Plasma quercetin metabolites: structure-antioxidant activity relationships. Arch Biochem Biophys 2004; 432: 109-121.
36. Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I et al. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther 2004; 9: 77-84.
37. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772-779.
38. Kirby B, Kharasch ED, Thummel KT, Narang VS, Hoffer CJ, Unadkat JD. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. J Clin Pharmacol 2006; 46: 1313-1319.